Droplet IV Raises $2M to Revolutionize IV Infusions—Ensuring Every Drop Reaches the Patient!

Droplet IV is thrilled to announce that we have raised US$2,000,000 in our latest funding round—a significant step forward in our mission to revolutionize intravenous therapy. Founded by a dedicated team of doctors and engineers, Droplet IV emerged from the BioMedical Design Novo Nordisk Foundation Fellowship Programme and is currently accelerating its growth within the Venture House incubator program at BioInnovation Institute. Our innovative technology automatically flushes IV lines to ensure patients receive the full, prescribed dose of medication every time, addressing a critical shortfall where approximately 20% of IV medicine is trapped as residual medication. This gap not only leads to dangerous underdosing but also places an unsustainable burden on nurses who currently spend an average of 2-3 minutes manually flushing each IV line—a challenge exacerbated by the global nursing shortage. With over 6 billion IV infusions administered worldwide every year and no true automatic flushing systems on the market today, our technology stands poised to transform patient care on a massive scale. The funds raised will be dedicated to further refining our innovative product, scaling production, and expanding our market reach. Moreover, this investment will help us enhance our platform to reduce nurse multitasking, eliminate wasted medicines, and even fight antibiotic resistance by preventing residual antibiotics from entering the environment. At Droplet IV, we pride ourselves on cultivating a holistic company culture where personal and professional growth go hand in hand with groundbreaking innovation. As we often say in our team, “Medicine belongs in patients – not in the trash!” We are excited about the opportunities ahead and invite you to join us on this transformative journey in modern MedTech.